Novartis receives EU approval for breast cancer drug Kisqali

Share this post

ZURICH (Reuters) – Novartis AG said its drug Kisqali (ribociclib) received European Union approval as first-line treatment for a tough-to-treat breast cancer, bolstering the Swiss drugmaker’s bid to challenge U.S. rival Pfizer’s Ibrance.

This post was syndicated from Reuters: Health News. Click here to read the full text on the original website.


Share this post

Be the first to comment

Leave a Reply